Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003)

Sugimura, Keijiro; Yamasaki, Makoto; Yasuda, Takushi; Yano, Masahiko; Hirao, Motohiro; Fujitani, Kazumasa; Kimura, Yutaka; Miyata, Hiroshi; Motoori, Masaaki; Takeno, Atsushi; Shiraishi, Osamu; Makino, Tomoki; Kii, Takayuki; Tanaka, Koji; Satoh, Taro; Mori, Masaki; Doki, Yuichiro

doi:https://doi.org/10.1002/ags3.12388

Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003)

Sugimura, Keijiro; Yamasaki, Makoto; Yasuda, Takushi et al.

Annals of Gastroenterological Surgery, 2020, 5(1), 75-82

アクセス数:515件（2025-04-28 19:57 集計）

固定URL: https://hdl.handle.net/11094/78301

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ags3.12388	pdf	なし	728 KB	160	2021.01.15

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003)
著者	NRID 1000000571374 1000000571374 著者名 Sugimura, Keijiro
	NRID 1000050444518 1000050444518 著者名 Yamasaki, Makoto
	NRID 1000010324782 1000010324782 著者名 Yasuda, Takushi
	NRID 1000070273646 1000070273646 著者名 Yano, Masahiko
	著者名 Hirao, Motohiro
	著者名 Fujitani, Kazumasa
	NRID 1000080716994 1000080716994 著者名 Kimura, Yutaka
	NRID 1000080362713 1000080362713 著者名 Miyata, Hiroshi
	著者名 Motoori, Masaaki
	著者名 Takeno, Atsushi
	NRID 1000070388536 1000070388536 著者名 Shiraishi, Osamu
	NRID 1000080528620 1000080528620 researchmap permalink _-_-_- _-_-_- Scopus Author ID 56339970700 56339970700 著者名 Makino, Tomoki
	著者名 Kii, Takayuki
	NRID 1000070621019 1000070621019 ORCID 0000-0001-5178-9388 0000-0001-5178-9388 researchmap permalink koji_tanaka koji_tanaka Scopus Author ID 55628548952 55628548952 著者名 Tanaka, Koji
	著者名 Satoh, Taro
	NRID 1000070190999 1000070190999 著者名 Mori, Masaki
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 著者名 Doki, Yuichiro
キーワード等	esophageal cancer
	neoadjuvant chemotherapy
	squamous cell carcinoma
内容	Sugimura, K, Yamasaki, M, Yasuda, T, et al. Long‐term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5‐fluorouracil vs docetaxel, cisplatin, and 5‐fluorouracil followed by surgery for esophageal cancer (OGSG1003). Ann. Gastroenterol. Surg. 2020; 00: 1– 8. https://doi.org/10.1002/ags3.12388.
抄録	Aim: The aim is to report the long-term outcomes of preoperative cisplatin and fluorouracil plus docetaxel (DCF) vs Adriamycin (ACF) for resectable esophageal squamous cell carcinoma (ESCC). Previously, this trial showed that DCF is associated with prolonged recurrence-free survival (RFS). Methods: Patients were randomly assigned to two cycles of ACF (35 mg/m2 of Adriamycin, 70 mg/m2 of cisplatin intravenously on day 1, and 700 mg/m2 of fluorouracil infusion for 7 days) every 4 weeks or DCF (70 mg/m2 of docetaxel, 70 mg/m2 of cisplatin intravenously on day 1, and 700 mg/m2 of fluorouracil infusion for 5 days) every 3 weeks, followed by surgery. The primary endpoint was RFS. The secondary endpoint was overall survival (OS). Results: Between October 2011 and October 2013, 162 patients at 10 institutions were enrolled in the study, 162 of whom were eligible and randomly assigned to the two groups. The median follow-up for surviving patients was 69.8 months. The 5-year RFS was significantly better in the DCF group than in the ACF group (59.9% vs 40.7%, hazard ratio [HR] 0.55; 95% confidence interval [CI], 0.35-0.86; P =.009) and the 5-year OS was significantly better in the DCF group than in the ACF group (63.5% vs 49.4%, HR, 0.61; 95% CI, 0.38-0.96; P =.03). The benefit of DCF chemotherapy on survival was significantly greater in the subgroups with more advanced clinical T and N stage. Conclusions: Cisplatin and fluorouracil plus docetaxel are associated with better RFS and OS than ACF in resectable ESCC patients.
出版者	John Wiley & Sons
収録物名	Annals of Gastroenterological Surgery
巻(号)	5(1)
ページ	75-82
刊行年月	2020-11-28
言語	英語
ハンドルURL	https://hdl.handle.net/11094/78301
eISSN	24750328
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1002/ags3.12388
アクセス権	open access
権利情報	© 2020 The Authors. This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Annals of Gastroenterological Surgery. 2020, 5(1), p. 75-82
DC.title	Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003)
DC.creator	Sugimura, Keijiro
	Yamasaki, Makoto
	Yasuda, Takushi
	Yano, Masahiko
	Hirao, Motohiro
	Fujitani, Kazumasa
	Kimura, Yutaka
	Miyata, Hiroshi
	Motoori, Masaaki
	Takeno, Atsushi
	Shiraishi, Osamu
	Makino, Tomoki
	Kii, Takayuki
	Tanaka, Koji
	Satoh, Taro
	Mori, Masaki
	Doki, Yuichiro
DC.publisher	John Wiley & Sons
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2020-11-28
DC.identifier	https://doi.org/10.1002/ags3.12388
DC.subject	esophageal cancer
	neoadjuvant chemotherapy
	squamous cell carcinoma
DC.description	Sugimura, K, Yamasaki, M, Yasuda, T, et al. Long‐term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5‐fluorouracil vs docetaxel, cisplatin, and 5‐fluorouracil followed by surgery for esophageal cancer (OGSG1003). Ann. Gastroenterol. Surg. 2020; 00: 1– 8. https://doi.org/10.1002/ags3.12388.
DCTERMS.abstract	Aim: The aim is to report the long-term outcomes of preoperative cisplatin and fluorouracil plus docetaxel (DCF) vs Adriamycin (ACF) for resectable esophageal squamous cell carcinoma (ESCC). Previously, this trial showed that DCF is associated with prolonged recurrence-free survival (RFS). Methods: Patients were randomly assigned to two cycles of ACF (35 mg/m2 of Adriamycin, 70 mg/m2 of cisplatin intravenously on day 1, and 700 mg/m2 of fluorouracil infusion for 7 days) every 4 weeks or DCF (70 mg/m2 of docetaxel, 70 mg/m2 of cisplatin intravenously on day 1, and 700 mg/m2 of fluorouracil infusion for 5 days) every 3 weeks, followed by surgery. The primary endpoint was RFS. The secondary endpoint was overall survival (OS). Results: Between October 2011 and October 2013, 162 patients at 10 institutions were enrolled in the study, 162 of whom were eligible and randomly assigned to the two groups. The median follow-up for surviving patients was 69.8 months. The 5-year RFS was significantly better in the DCF group than in the ACF group (59.9% vs 40.7%, hazard ratio [HR] 0.55; 95% confidence interval [CI], 0.35-0.86; P =.009) and the 5-year OS was significantly better in the DCF group than in the ACF group (63.5% vs 49.4%, HR, 0.61; 95% CI, 0.38-0.96; P =.03). The benefit of DCF chemotherapy on survival was significantly greater in the subgroups with more advanced clinical T and N stage. Conclusions: Cisplatin and fluorouracil plus docetaxel are associated with better RFS and OS than ACF in resectable ESCC patients.
DC.rights	© 2020 The Authors. This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	78301
citation_title	Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003)
citation_author	Sugimura, Keijiro
	Yamasaki, Makoto
	Yasuda, Takushi
	Yano, Masahiko
	Hirao, Motohiro
	Fujitani, Kazumasa
	Kimura, Yutaka
	Miyata, Hiroshi
	Motoori, Masaaki
	Takeno, Atsushi
	Shiraishi, Osamu
	Makino, Tomoki
	Kii, Takayuki
	Tanaka, Koji
	Satoh, Taro
	Mori, Masaki
	Doki, Yuichiro
citation_publisher	John Wiley & Sons
citation_language	英語
citation_date	2020-11-28
citation_journal_title	Annals of Gastroenterological Surgery
citation_volume	5
citation_issue	1
citation_firstpage	75
citation_lastpage	82
citation_doi	https://doi.org/10.1002/ags3.12388
citation_public_url	https://hdl.handle.net/11094/78301

Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003)

閲覧可能ファイル

論文情報

論文詳細を表示